Summary & Overview
HCPCS Level II A9598: PET Radiopharmaceutical for Non-Tumor Diagnostic Imaging
HCPCS Level II code A9598 designates a PET radiopharmaceutical for diagnostic non-tumor identification that is not otherwise classified. This code covers the administered radiotracer product used during PET imaging when the clinical intent is non-oncologic diagnostic evaluation. Nationally, PET radiopharmaceuticals support clinical decision-making across neurology, cardiology, and other non-tumor indications, making clear coding important for billing consistency, coverage determination, and resource allocation.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical scope, typical sites of service, and the role of A9598 in non-tumor PET imaging workflows. The publication summarizes common billing modifiers and payer coverage context, outlines typical service settings, and highlights where policy updates or coding clarification may affect claim processing. The content is intended to inform coding staff, revenue cycle professionals, and policy analysts about the code’s purpose, expected clinical uses, and considerations for national billing practices.
Billing Code Overview
HCPCS Level II code A9598 represents a positron emission tomography (PET) radiopharmaceutical used for diagnostic imaging in non-tumor identification, not otherwise classified. The code covers the radiopharmaceutical agent itself when used to support PET imaging for indications other than tumor detection.
-
Service type: Diagnostic radiopharmaceutical administration for PET imaging
-
Typical site of service: Imaging centers or hospital outpatient departments where PET scans are performed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with a history of neurodegenerative symptoms is referred for a diagnostic positron emission tomography (PET) radiopharmaceutical scan for non-tumor brain pathology evaluation. The referring neurologist documents progressive cognitive decline and atypical movement features to distinguish Alzheimer disease, Parkinson disease, or other parkinsonian syndromes. The patient arrives at an outpatient nuclear medicine department. Verification of identity, allergy history, medication review (including recent contrast or radiopharmaceutical exposures), and informed consent are completed. The nuclear medicine technologist administers the appropriate PET radiopharmaceutical designated for non-tumor brain imaging. The patient rests for the uptake period, is positioned on the PET/CT scanner, and acquisition is performed according to protocol. A radiopharmacist documents lot and dose; a nuclear medicine physician interprets the images and generates a report describing regional tracer distribution to aid differential diagnosis. Billing uses HCPCS Level II code A9598 for the radiopharmaceutical; professional and technical components may be billed separately using appropriate modifiers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing physician interpretation/report separate from technical component |